International randomized phase II trial of the combination of Vincristine and Irinotecan with or without Temozolomide (VI or VIT) in children and adults with refractory or relapsed rhabdomyosarcoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
At a glance
- Drugs Temozolomide (Primary) ; Irinotecan; Vincristine
- Indications Rhabdomyosarcoma
- Focus Therapeutic Use
- 14 Jun 2018 Planned End Date changed from 1 Sep 2021 to 1 Sep 2023.
- 02 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2017 Planned End Date changed from 31 Dec 2021 to 1 Sep 2021.